These two medications get discussed as though they were the same drug at different price points. They are not. They work through different mechanisms, and that difference is the reason their results differ.
Here is what actually separates them, and how the choice gets made.
One receptor versus two
Semaglutide is a GLP-1 receptor agonist. It mimics GLP-1, a hormone your gut releases after eating. That hormone slows how quickly the stomach empties, prompts insulin release when blood sugar rises, and acts on appetite centres in the brain. The practical effect is that you feel full sooner and stay full longer, and the constant background noise about food quietens.
Tirzepatide does that same thing and one more. It is a dual agonist, acting on both the GLP-1 receptor and the GIP receptor. GIP is another gut hormone involved in insulin response and fat metabolism. Engaging both pathways appears to produce a larger effect on both blood sugar and weight than engaging GLP-1 alone.
That is the whole mechanical difference, and it is the reason the outcomes differ.
What the trials showed
Both medications have been studied in large randomized trials, and both produced weight loss well beyond what lifestyle intervention achieves on its own.
In the trials of semaglutide at the dose used for weight management, average weight loss was in the region of fifteen percent of body weight over roughly sixteen months. In the equivalent trials of tirzepatide, average loss at the higher doses reached roughly twenty to twenty-two percent over a similar period.
Two things are worth saying about those figures. First, they are averages — individual results in both trials ranged widely, and a meaningful minority of participants responded far less than average to either drug. Second, trial conditions include structured support and monitoring that is part of why the numbers look the way they do. The medication is not the entire intervention.
Brand names, and why they confuse people
Semaglutide is sold as Ozempic for type 2 diabetes and as Wegovy for weight management. Tirzepatide is sold as Mounjaro for type 2 diabetes and as Zepbound in some markets for weight management. Same molecule, different brand, different approved indication and dosing.
Availability of each brand and indication varies in Canada and changes over time, which is part of what a prescriber is tracking on your behalf.
Side effects
Largely the same for both, and largely gastrointestinal: nausea, constipation or diarrhoea, reflux, and reduced appetite to a degree that can itself become a problem. These are most pronounced after a dose increase and usually settle as the body adjusts.
Most of the misery people describe with these medications comes from escalating the dose too quickly. Titration exists precisely to avoid that, and going slower is almost always the right answer when symptoms are difficult. There is rarely a prize for reaching the top dose quickly.
There are also situations where neither medication is appropriate — certain personal or family histories, some gastrointestinal conditions, pregnancy or planned pregnancy. That screening is a required part of starting, not a formality.
Muscle, and why it matters
This gets too little attention. Rapid weight loss from any cause takes lean tissue as well as fat, and losing muscle is not a neutral outcome — it affects metabolic rate, strength, bone loading and how you feel day to day.
Protein intake and resistance training are not optional extras alongside these medications. They are what determines whether the weight you lose is the weight you wanted to lose. A program that hands over a prescription without addressing this is doing half the job.
Cost, and the honest part about stopping
Tirzepatide is generally the more expensive of the two, and neither is cheap. Coverage through extended health benefits varies by plan and by indication, and is worth checking before starting rather than after.
The harder question is what happens when you stop. The trial data on both medications shows substantial regain after discontinuation. These medications treat an ongoing physiological process; they do not permanently reset it. For many people that means thinking about this as long-term treatment rather than a course with an end date.
That is a legitimate thing to weigh up before starting, and it deserves a straight answer rather than being discovered a year in.
So which one
It depends on more than the headline percentage. Your starting point and goals. Whether blood sugar or insulin resistance is part of the picture. How you tolerated anything you have tried before. Cost and coverage. Availability. And sometimes simply starting with one and reassessing honestly at three months.
At Juvenescence Wellness, both are prescribed and monitored by Stephanie Eschak, Nurse Practitioner, as part of a structured program — clinical intake, baseline bloodwork, dose titration, regular review, and a plan for what happens longer term. The bloodwork and the prescribing stay with the same clinician, which keeps the whole picture in one place.
If you want the broader context on how a supervised program is built, this piece on medical weight loss covers what gets assessed and why supervision changes outcomes.
Written by Stephanie Eschak, Nurse Practitioner, at Juvenescence Wellness in Lake Cowichan, BC. This article is general information, not medical advice for your individual situation. Book a consultation or call 250·932·6171.